A Global, Pivotal, Placebo-Controlled Phase 2/3 Efficacy and Safety Study of WVE-210201 in Duchenne Muscular Dystrophy (DMD) Patients Amenable to Exon 51 Skipping
Phase of Trial: Phase II/III
Latest Information Update: 06 Dec 2018
At a glance
- Drugs WVE 210201 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Sponsors WaVe life Sciences
- 06 Dec 2018 According to a WaVe life Sciences media release, study anticipates initiating in 2019.
- 29 Aug 2018 New trial record
- 09 Aug 2018 According to a WaVe life Sciences media release, this study will be powered to assess clinical efficacy and will include dystrophin expression readouts as part of interim and final analyses.